DJIA 17,814.94 -2.96 -0.02%
NASDAQ 4,758.25 3.36 0.07%
S&P 500 2,067.03 -2.38 -0.12%
market minute promo

Merck & Co., Inc. (NYSE: MRK)



company name or ticker
Company Photos
(Click to zoom)

BIND Therapeutics Offers Great Potential With Upcoming Catalyst

Achillion Pharmaceuticals: Still Bullish, But Taking Profits

U.S. gene study raises hope for Merck cholesterol drug Zetia

Sub-Optimal 39% Hep C Cure Rate Keeps Merck In Gilead's Rear View

Pandering Your Wealth Away

Pay no attention to these guys.

Gilead Sciences Releases Impressive Results for Hepatitis C Drug

Bill Ackman's Latest Target: Zoetis Inc.

Bill Ackman's latest investment is in Zoetis, an animal health business with more than $4 billion in annual sales.

This Tiny Biotech Is Piggybacking on Gilead Sciences, Inc.'s Success

Achillion Pharmaceuticals is working on an adjunct therapy that could significantly reduce the number of weeks hepatitis C patients would require treatment.

After Hours Most Active for Nov 11, 2014 : DG, MRK, ONNN, MU, ARCP, FOSL, LNCO, SPF, PBR, ISIS, BAC

After Hours Most Active for Nov 11, 2014 : DG, MRK, ONNN, MU, ARCP, FOSL, LNCO, SPF, PBR, ISIS, BAC, LLY

Dow Analyst Moves: MRK

See More Articles...